US/UK/Canada

Share

Contacts

  • Cyxone AB
    Hyllie Boulevard 34, 215 32 Malmö, Sweden
    +46 708882172
    +46 708882172
    https://cyxone.com/en/

    • Quotes

    We are happy to announce the positive study outcomes, an instrumental part of the preparations for the Phase 2 study in RA patients set to start late next year. Equally, we are eagerly looking forward to the imminent initiation of our clinical study of Rabeximod in Covid-19 patients. Combined with the new patent applications recently filed, with potential to substantially prolong market exclusivity, and with a stockpile of drug substance enabling further clinical studies beyond those currently in the pipeline, we stand with a strong foothold in future partnering negotiations. All in all, Cyxone is well-positioned for the development of safe and innovative treatments toward serious immune system disorders.
    Tara Heitner, CEO, Cyxone
    After thorough evaluation, we were able to decide upon this CRO as our partner of choice for these preclinical studies. The selected CRO has an excellent reputation and we got a great impression of their quality and professionalism from the start. We now look forward to take the next step in the development program for our Phase II candidate Rabeximod.
    Malin Berthold, Head of Project Management at Cyxone
    This market maker is now being implemented to increase liquidity of our stock, which has sometimes been low. We look very favorably on this support measure, which is primarily done to benefit our shareholders through reduced trading risks.
    Kjell G. Stenberg, CEO of Cyxone
    The acquisition of Rabeximod is the most important milestone since Cyxone was founded. I have been following Rabeximod's development in OxyPharma for a long time and believe that this investment is very beneficial for our shareholders. We have in a short time been able to build a world-class autoimmune product portfolio, which has permeated the discussions we have had with different stakeholders regarding the financing of Rabeximod's phase IIb study. This is why we are now taking the opportunity to complete the payment and hope to return soon to our shareholders with more positive news regarding Rabeximod.
    Kjell G. Stenberg, CEO of Cyxone
    Pick a time period -
    Tags ( Active)

    Cyxone AB announces last day of trading in BTA

    Cyxone AB’s ("Cyxone" or the "Company") rights issue, with a subscription period ending on 15 August 2024, has now been registered at the Swedish Companies Registration Office. The Company hereby announces that the last day of trading in BTA (paid subscribed share) is 29 August 2024, and the stop day is 2 September 2024.In August 2024, Cyxone carried out a rights issue which provided the Company with approximately SEK 6.4 million before issue costs. The previously communicated outcome was lacking a subscription of SEK 67,419.20 and this subscription has thus been added to the numbers below.

    Cyxone AB publishes outcome of rights issue

    The subscription period in Cyxone AB’s ("Cyxone" or the "Company") rights issue ended on 15 August 2024 (the "Rights Issue"). The Rights Issue was subscribed to a total of approximately 27.3 percent, including pre-subscription commitments. Cyxone will thus be provided proceeds of approximately SEK 6.3 million before deduction of transaction related costs.Subscription, allocation and payment The Rights Issue was subscribed to approximately SEK 6.3 million including pre-subscription commitments of approximately SEK 0.26 million, which corresponds to a subscription rate of approximately 27.

    The subscription period in Cyxone’s rights issue starts today

    Today, 1 August 2024, the subscription period in Cyxone AB’s ("Cyxone" or "the Company") issue of shares (the "Rights Issue") of a maximum of SEK 23 million, with preferential right for the Company's existing shareholders, begins. The purpose of the capital acquisition is primarily to finance development programs with exploratory studies with the drug candidate rabeximod for patients who do not respond well to TNFa inhibitors and to finance development of T20K. The subscription period runs until 15 August 2024. A memorandum is available via the Company's (www.cyxone.com) website.NOT FOR

    Cyxone AB publishes investment memorandum

    On 23 July 2024, the board of Cyxone AB (publ) ("Cyxone" or the "Company"), resolved to carry out a preferential rights issue of shares (the "Rights Issue"). Prior to the Rights Issue, Cyxone has prepared an investment memorandum containing information about the Company and the Rights Issue, which is now available via the Company's website (www.cyxone.com). The subscription period begins on 1 August 2024 and lasts until 15 August 2024.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND,

    The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K

    The board of Cyxone AB (publ), corporate no. 559020-5471, ("Cyxone" or the "Company") has today resolved on a new issue of shares with preferential rights for the Company's existing shareholders for a total of approximately SEK 23 million before deductions for transaction costs (the "Rights Issue"). The decision has been made with the support of authorization from the annual general meeting in 2024. The purpose of the capital acquisition is primarily to finance development programs with exploratory studies with the drug candidate rabeximod for patients who do not respond well to TNFa

    Cyxone provides an update on its research and development program

    Cyxone (publ) is a biotech company with two promising clinical stage drug candidates, rabeximod and T20K, for autoimmune diseases. The company announces an updated development plan that aligns with the revised strategy revealed in August 2023, aiming to bring hope to patients suffering from these conditions.In April of this year, Kjell Stenberg, a seasoned leader in the biotech industry, was appointed as the company's new CEO. In collaboration with an external team of key opinion leaders and an internal team, Dr. Stenberg reviewed the latest findings for both the rabeximod and T20K projects.

    Kjell Stenberg new CEO in Cyxone AB

    Cyxone AB (publ), a biotech company in autoimmune diseases, has decided to appoint Kjell Stenberg as new CEO with immediate effect. Kjell replaces Carl-Magnus Högerkorp, who will ensure a smooth transition.Kjell was the CEO of Cyxone from when the company was founded in 2015 until 2019. He has thus good knowledge of Cyxone’s projects, which facilitates a seamless change of management. Kjell holds a PhD in medical science, has held management positions in AstraZeneca R&D including project inlicensing from biotech. Since 2001 he has worked in biotech and with corporate financing in Europe

    BioStock: Cyxone comments on the clinical collaboration in the UK

    Cyxone has entered into a research collaboration with a renowned British research group in Glasgow with the aim of conducting an exploratory phase II study with rabeximod in rheumatoid arthritis patients. BioStock reached out to CEO Carl-Magnus Högerkorp, who highlights the research group’s collaboration with the universities of Birmingham, Newcastle, and Oxford in the field.Read the full interview with Carl-Magnus Högerkorp at biostock.se: https://www.biostock.se/en/2024/03/cyxone-comments-on-the-clinical-collaboration-in-the-uk/ This is a press release from BioStock - Connecting

    Cyxone enters important research collaboration

    Cyxone (publ), a biotech company in autoimmune diseases, enters into a strategically important research collaboration with an acknowledged research group at University of Glasgow, UK, with the objective of performing an exploratory phase 2 study with rabeximod in patients with rheumatoid arthritis (RA).https://cyxone.com/en/The research group at School of Infection and Immunity, University of Glasgow is an internationally recognised centre of excellence conducting high quality basic, translational and clinical research in the disciplines of infection, immunology and inflammation. The

    BioStock: Cyxone’s CEO gives a status update

    Cyxone recently reached a milestone in its rheumatoid arthritis project, rabeximod, when succeeding in identifying the molecule’s target protein. This means that it is now easier to identify other diseases in which this mechanism of action plays an important role. BioStock reached out to CEO Carl-Magnus Högerkorp for a comment on the company’s year-end report for 2023.Read the full interview with Carl-Magnus Högerkorp at biostock.se: https://www.biostock.se/en/2024/03/cyxones-ceo-gives-a-status-update/ This is a press release from BioStock - Connecting Innovation & Capital. https://

    BioStock: Cyxone identifies target protein for rabeximod

    Cyxone has put intense focus on the development of lead candidate rabeximod - an immunomodulatory treatment for rheumatoid arthritis. The company has now produced important research results that provide a more detailed insight into the drug candidate's mechanism of action. The company's CEO Carl-Magnus Högerkorp tells us more in an interview.Read the full article at biostock.se : https://www.biostock.se/en/2024/01/cyxone-identifies-target-protein-for-rabeximod/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    Cyxone reaches important milestone regarding mechanism of action

    Cyxone (publ), a biotech company in autoimmune diseases, has reached an important milestone for the drug candidate rabeximod. Recently, the biological target protein for rabeximod was identified, a finding that has now been confirmed in an independent scientific analysis. This important milestone represents a major step forward for the project as the new knowledge contributes to an increased understanding of the drug's mechanism of action and confirms its First-in-Class status.Rabeximod is an immunomodulatory drug that has shown selectivity for pro-inflammatory macrophages and dendritic

    Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor

    Cyxone (publ), a biotech company in autoimmune diseases, re-engages Professor Rikard Holmdahl as Scientific Advisor for the company’s projects in autoimmune diseases.Rikard Holmdahl has long established experience and expert knowledge in immunology and autoimmune diseases. Professor Holmdahl is one of Sweden’s leading scientists in immunology who has contributed to very valuable insights into the mechanisms causing chronic inflammatory diseases such as multiple sclerosis and rheumatoid arthritis. He has during his career been acknowledged with several prestigious scientific prizes for his

    Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K

    Cyxone (publ), a biotech company in autoimmune diseases announces that the European Patent Office (EPO) has issued an intention to grant communication for a unitary patent of the divisional EP-Divisional Patent Application 18 172 126.7 entitled Cyclotides as immunosuppressive agents. The patent covers the protection of the drug candidate T20K that Cyxone licenses from the Medical University of Vienna and the University of Freiburg.The European patent office announced that the patent application will be granted as a unitary patent as of November 1[st], 2023, and will be valid in the

    BioStock Investor Meeting: Cyxone

    Cyxone presented at BioStock Investor Meeting, September 20. The event took place in Stockholm, featuring several exciting life science companies presenting their business cases to investors and potential partners.See the presentation via: BioStock Investor Meeting September 2023 | Cyxone - YouTube  See the interview via:  BioStock Investor Meeting | Interview with Cyxone | September 2023 - YouTube  This is a press release from BioStock - Connecting Innovation & Capital. https://www.

    Cyxone revises strategy for commercial alignment targeting valuable market opportunities

    Cyxone (publ), a biotech company in autoimmune diseases, with its lead asset rabeximod under development in rheumatoid arthritis, is revising its previous strategy due to important patent grants and valuable market opportunities.During 2023 a range of new biosimilar disease modifying anti-rheumatic drugs (DMARDs), approved by the US Food and Drug Administration, FDA, have been broadly introduced to the American market. As a result, patients with moderate to severe rheumatoid arthritis that have inadequate response to methotrexate will now be offered a range of less costly TNFa inhibitor

    Cyxone appoints Urban Ottosson as new CFO

    Cyxone (publ), a biotech company in autoimmune diseases, has recruited Urban Ottosson as new Chief Financial Officer (CFO) as of June 15[th] 2023, replacing Ola Skanung.Urban has a M.Sc. in Business and Economics degree from Lund university and has attained an Executive Diploma from KTH Executive School in Stockholm. He has held several CFO positions in a range of publicly listed companies and has a strong background in M&A, business strategy, Investor Relations, and financial management. Urban will succeed Ola Skanung, who has been the company´s CFO since 2022 as well as previous years

    Cyxone receives Intention to Grant from the European Patent Office for the divisional patent of T20K

    Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that the European Patent Office has issued an intention to grant communication for EP-Divisional Patent Application 18 172 126.7 entitled Cyclotides as immunosuppressive agents. The application covers the protection of the drug candidate T20K that Cyxone licenses from the Medical University of Vienna and the University of Freiburg.The intention to grant is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as

    Bulletin from the annual general meeting in Cyxone AB on 30 May 2023

    The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Today, on 30 May 2023, the annual general meeting was held in Cyxone AB. A summary of the adopted resolutions follows below.Resolution on adoption of accounts and allocation of the company’s result The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet. The annual general meeting also resolved in accordance with the

    Cyxone receives patent approval from the US for the salt forms of the compound rabeximod

    Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that the company has obtained granted status for the US patent application 17/891,462 entitled Rabeximod Compounds from the United States Patent and Trademark Office (USPTO).The application covers the protection of salt forms of the compound rabeximod which is being developed as treatment for moderate to severe rheumatoid arthritis. The patent will be valid until 2042. ”We are delighted to receive the final approval for this important patent. It is an essential fundament for the future development and

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media